Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 17/20 | 0.90 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.90 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.73 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.73 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622006 | 0.95 | FYN (1.00) | TGFBR1FYNCHEK2 | |
| SCHEMBL30521680 | 0.95 | FYN (1.00) | TGFBR1FYNCHEK2 | |
| SCHEMBL18860392 | 0.89 | TGFBR1 (0.81) | TGFBR1FYNCHEK2CHEK1 | |
| SCHEMBL17110829 | 0.88 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL30521681 | 0.88 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL18613288 | 0.88 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL18613265 | 0.86 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL18613514 | 0.85 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL29358327 | 0.85 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 | |
| SCHEMBL16026073 | 0.85 | FYN (1.00) | TGFBR1FYNCHEK2BMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-10-26 | — | — | US | disclosed |
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-10-26 | — | — | US | disclosed |
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-10-26 | — | — | US | disclosed |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-06 | — | — | US | disclosed |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-06 | — | — | US | disclosed |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-06 | — | — | US | disclosed |
| EP-3122355-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | The Brigham and Women's Hospital, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148654-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305883-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | TGFBR1 44/4885FYN 4175/4885CHEK2 2470/4885 |
| US-20170190705-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | TGFBR1 43/4885FYN 4165/4885CHEK2 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.